Scientists have developed a new method to administer the cancer drug pembrolizumab, reducing treatment time from hours to minutes. By studying how the drug forms crystals in microgravity aboard the International Space Station, researchers identified ways to create more uniform and stable crystals. This discovery enabled the development of a subcutaneous injection formulation, approved by the FDA in September 2025, replacing the previous lengthy intravenous infusion. The new method significantly cuts down patient and doctor time, reduces costs, and improves the quality of life for cancer patients.